Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1637 1641 1642 1674
This examiner grants 71% of resolved cases
Jon E. Angell has resolved 827 cases in Art Unit 1635 within Tech Center 1600. The allowance rate is 71.0%, and the median days to allowance is 1194. This shows a favorable environment for applicants, with a high probability of success. The 1194-day median pendency provides a clear expectation for the duration of the prosecution process.
The interview lift is 21.1%, indicating that interviews are a productive strategy for improving outcomes. This lift can enhance the 71.0% base allowance rate, making direct engagement a valuable tool for practitioners. With 827 resolved cases, the data suggests that the examiner is open to resolving issues through verbal discussion. Practitioners should consider the 21.1% lift as a way to navigate the 1194-day timeline more effectively. The 71.0% allowance rate remains a solid foundation for successful prosecution in this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18192108 | DOUBLE-STRANDED RNA THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN AND PHARMACEUTICAL COMPOSITION | Non-Final OA | FUJIFILM Corporation |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17637427 | TARGETING SLC38A2 IN PANCREATIC CANCER | Non-Final OA | New York University |
| 18309548 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING OR REVERSING OBESITY AND OBESITY-RELATED DISORDERS BY OPSIN 3 REGULATION OF HYPOTHALAMIC MELANOCORTIN RECEPTORS | Non-Final OA | Brown University |
| 18131892 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 16971604 | ANALYSIS/DIAGNOSIS METHOD UTILIZING RNA MODIFICATION | Final Rejection | OSAKA UNIVERSITY |
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18012867 | ARTIFICIAL RNAS FOR MODULATING RNA FRAGMENTS | Final Rejection | UNIVERSITAT POMPEU FABRA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy